April 14-19, 2023 | Orange County Convention Center | Orlando, FL

Sapient is excited to join the cancer research community for this prestigious event which will facilitate important discussions to advance cancer treatment, prevention, and cures.
If you’ve been wanting to learn more about discovery metabolomics and the applications of small molecule biomarkers in your oncology programs – from target identification to immunotherapy safety profiling to enriching cancer clinical trials – then we invite you to meet up with our team during AACR in the following ways:
Visit us at Bruker’s Booth #1818
Bruker is a valued partner to Sapient and has invited us to join their booth space this year. Stop by to see Bruker’s latest bioanalytical and diagnostic innovations and to meet with Sapient’s attending team members, including Dr. Tanya Nguyen, Head of Scientific Operations, and Dr. Phil Worboys, Head of Translational Science. You can learn how we leverage Bruker’s timsTOF Pro 2 systems as part of our rLC-MS platform to enable high-throughput, nontargeted biomarker discovery across broad chemistries.
Pre-schedule an on-site meeting
Have specific questions or potential programs you’d like to discuss? We would love to talk through your needs and how we can partner together to accelerate your drug discovery and development efforts. Use this link to preschedule a 1-on-1 meeting time during AACR.

Join us at AACR 2023
April 14-19, 2023 | Orange County Convention Center | Orlando, FL Sapient is excited to join the cancer research community for this prestigious event which will facilitate important discussions to advance cancer treatment, prevention, and cures. If… Read More

Technology Networks Feature: “Probing the Biomarker Landscape of Human Disease”
Technology Networks’ Anna MacDonald sat down with Sapient’s Dr. Mo Jain for this Industry Insights piece to discuss the importance of improving biomarker discovery and how next-generation mass spectrometry (MS)-based systems can help to fill the current gap in biomarker technologies. Read an excerpt from the… Read More

Sapient Featured in Biocompare Article, “Mass Spectrometry for Biomarker Discovery”
Biocompare recently spoke to a panel of experts, including Sapient’s CEO and Founder, Dr. Mo Jain, to get their takes on the challenges and opportunities of using mass spectrometry for biomarker discovery and research. Dr. Jain shares his perspectives on how technological advances in mass spectrometry are “releasing the brakes”… Read More

University of Oxford Publishes Findings from Its INTERBIO-21st Study Supported by Sapient’s Discovery Metabolomics
September 1, 2022—San Diego, CA—A study led by researchers at the University of Oxford, UK has been published in Lancet Diabetes & Endocrinology, detailing findings which identify putative metabolic pathways that influence fetal growth trajectories and childhood health outcomes. Sapient provided mass spectrometry-based discovery metabolomics… Read More

Sapient Featured as Collaborator in Cedars-Sinai Study on Immune Responses and COVID-19
Study infrastructure and biospecimen processing support is being provided by Sapient for the study, which is focused on advancing vital immune response research for COVID-19 and other autoimmune and inflammation-associated diseases. Cedars-Sinai’s press release highlights key study findings now published in JAMA Network Open on COVID-19 infection awareness rates, indicating… Read More

Sapient Receives $9.2M Grant for Population-Scale Discovery Mass Spectrometry Analysis
The grant from Bill & Melinda Gates Foundation will support studies to identify biomarkers that can inform novel nutritional, disease-prevention, and disease-treatment interventions July 11, 2022—San Diego, CA—Sapient, a biomarker discovery organization focused on rapid, large-scale biomarker profiling, has been awarded a… Read More

Sapient Featured in Bruker Press Release Announcing timsTOF Innovations at ASMS 2022
“Sapient’s proprietary, next-generation rapid LC-MS (rLC-MS) technologies leverage the unique bioanalytical capabilities of the Bruker timsTOF Pro 2 system and enable nontargeted capture and measure of more than 11,000 circulating small molecule biomarkers – including thousands of yet uncharacterized factors – in a human biosample in less than one… Read More

Sapient Joins the Foundation for the National Institutes of Health Biomarkers Consortium
San Diego, CA—Sapient, a biomarker discovery organization transforming drug development through rapid, large-scale biomarker profiling, has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, the preeminent group of public-private partners focused on identifying, developing, and qualifying biomarkers to… Read More

Sapient’s Diagnostic Collaboration with Bay Area Lyme Foundation Featured in the Foundation’s Annual Impact Update Report
San Diego, CA—Sapient, a full-service bioanalytical organization transforming drug development through biomarker discovery, has been featured in the Bay Area Lyme Foundation’s 2021 Impact Update report for its collaboration with the Foundation aimed at establishing new diagnostics for persistent Lyme disease (PLD). The report… Read More

Philip Worboys, Ph.D. Joins Sapient as Head of Translational Science
San Diego, CA—Sapient, a full-service bioanalytical research organization transforming the efficiency of biomarker discovery for pharmaceutical and biotechnology sponsors, announced that Philip Worboys, Ph.D. has joined its leadership team as Head of Translational Science. In this role, Dr. Worboys will work with Sapient’s cross-functional teams to develop and execute scientifically… Read More